Plot twist: Aakash and I swapped days this week. He took my Tuesday slot (did you notice?), so you’re stuck with me for Therapeutic Thursday. Let’s dig in.
From being one of dermatology’s most neglected stories to becoming a potential multibillion-dollar treatment market being targeted by several large pharmas, hidradenitis suppurativa (HS) has experienced a sea change.
Dr. Steven Daveluy, whom I spoke with for a market snapshot I wrote about the disease in June, described the HS conferences of yore as quiet, close-knit affairs. “At our dermatology conferences, the room, when we talked about HS, used to be very small – you knew everyone in the room. But now that there’s [an] approved therapy, so many derms are re-engaging that the rooms are overfilled, standing room only,” said Daveluy, who is a professor of dermatology at Wayne State University in Detroit.
The treatment landscape has changed dramatically over the past few years. But conversations with dermatologists, analysts and pharma executives revealed some holes in the existing treatment paradigms and, with them, opportunities for new entrants.